EX 937
Alternative Names: EX-937; URB-937Latest Information Update: 24 Nov 2023
Price :
$50 *
At a glance
- Originator University of California at Irvine
- Class Antitussives; Small molecules
- Mechanism of Action Fatty acid amide hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cough
- Discontinued Migraine; Overactive bladder; Pain
Most Recent Events
- 07 Nov 2023 Discontinued - Preclinical for Migraine in USA (unspecified route) (Exxel Pharma pipeline, November 2023)
- 07 Nov 2023 Discontinued - Preclinical for Overactive bladder in USA (unspecified route) (Exxel Pharma pipeline, November 2023)
- 07 Nov 2023 Discontinued - Preclinical for Pain in USA (unspecified route) (Exxel Pharma pipeline, November 2023)